RFA-HG-22-008: Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 18, 2022.
From the official notice on Grants.gov, last changed September 7, 2022. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNHGRI, NCI
- Median yearly award$766,724
- Typical project length4.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HG-22-008 were run by National Human Genome Research Institute (NHGRI, 5 projects) and National Cancer Institute (NCI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HG-22-008 in the NIH Guide.
Key dates
| Posted | September 7, 2022 |
|---|---|
| Deadline | November 18, 2022 |
| Archived by Grants.gov | December 24, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $766,724; it allows up to $500,000 per award.
- Most of the money in the 4 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this Funding Opportunity Announcement (FOA) is to establish Disease Study Sites (DSS) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Omics Production Centers (RFA-HG-22-009) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Disease Study Sites will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. Each DSS will be primarily responsible for proposing a study focused on a disease area for which integrative multi-omics could be used to define associations with healthy and disease states and to detect changes over time. Each DSS will utilize effective strategies to enroll and consent participants, collect phenotypic and environmental exposure data, collect samples and measures over time, and contribute to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.
Funded under RFA-HG-22-008 so far
NIH funded 6 projects under RFA-HG-22-008 in fiscal 2023 to 2026, at 6 institutions. The median yearly award was $766,724.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Multi-Omics at the Intersections of Environment, Diabetes, and Kidney Disease: A Multi-Omics for Health and Disease Study Site | University of Illinois at Chicago | 2026 | $737,780 |
| Multi-omics for obesity-associated liver disease in a high-risk population cohort | University of Texas HLTH Sci Ctr Houston | 2026 | $1.1 million |
| Multi-Omics for Maternal Health after Preeclampsia | University of California, San Diego | 2026 | $760,183 |
| EXposomic Profiling in Airway disease to uNravel Determinants of disease in Asthma (EXPAND-Asthma) Center | University of California, San Francisco | 2026 | $724,224 |
| Multi-Omics for Chronic Kidney Disease | Columbia University Health Sciences | 2026 | $757,992 |
| Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study | University of Southern California | 2025 | $784,467 |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Who has won Environmental Health grants before
From fiscal 2021 to 2025, Environmental Health (93.113) awarded $2.1 billion across 1,980 grant awards, an average of $1.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | 49 | $87.7 million |
| The Trustees of Columbia University in the City of New York | New York | 69 | $78.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 59 | $71.5 million |
| Emory University | Georgia | 57 | $67.2 million |
| University of Southern California | California | 40 | $58.9 million |
Other programs behind this notice
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HG-22-008 still open?
No. It closed on November 18, 2022.
Who can apply for Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)?
Closed November 18, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-HG-22-008?
NIH RePORTER lists 6 projects funded under RFA-HG-22-008 in fiscal 2023 to 2026, at 6 institutions. The most were at University of Illinois at Chicago, University of Texas HLTH Sci Ctr Houston, University of California, San Diego.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)